Advocates for Community Health (ACH) was featured in 340B Report following the release of Senator Bill Cassidy’s discussion draft proposing significant changes to the 340B Drug Pricing Program. In the article, ACH Senior Vice President of Policy and Government Affairs Stephanie Krenrich emphasized ACH’s longstanding support for thoughtful 340B reform while expressing concerns that the […]
The Trump administration’s FY 2027 budget proposal seeks to move 340B program oversight from HRSA to CMS, while significantly increasing its funding. This move could signal a major shift in federal drug pricing policy, reports 340B Report. The proposed reorganization, which includes a 68% funding increase to $20.5 million for the Office of Pharmacy Affairs […]
Advocates for Community Health (ACH) is encouraged by the proposed HHS funding increase for the 340B Drug Pricing Program. Increased funding from $12.2 million to $20.5 million enables greater transparency and accountability across participating providers, and ensures manufacturers aren’t unduly restricting covered entities. ACH has advocated for increased funding for this very reason and looks […]
The drug industry this week celebrated its first federal appeals court victory against a state 340B contract pharmacy access law—a ruling which could face additional challenges, including before the U.S. Supreme Court, reports Shannon Young at 340B Report. The court ruling blocking West Virginia’s 340B contract pharmacy law sparked strong concern from providers and advocacy […]
A new KFF Health News article from Phil Galewitz spotlights Nebraska as an early test case for the impact of the newly enacted “One Big Beautiful Bill Act,” following federal approval of the state’s Medicaid work requirement program. In Nebraska, the policy could affect roughly 72,000 Medicaid expansion enrollees. While state officials say they will […]
Axios reports that the federal 340B drug pricing program—an $81 billion lifeline for safety-net providers—is facing mounting pressure from major pharmaceutical companies and new federal policy shifts. Stephanie Krenrich, who leads policy and government affairs at Advocates for Community Health, was recently interviewed for the article by Maya Goldman. Drugmakers like Eli Lilly and Novo […]
A recent 340B Report article from Luke Zarzecki highlights the ongoing efforts in Washington, D.C., to preserve the 340B drug pricing program for health centers and other safety-net providers. While some lawmakers are exploring 340B reforms, including rebate models and the proposed 340B ACCESS Act, the reality is that 340B is a vital lifeline. 340B […]
At a time when the 340B program is under increasing pressure, Advocates for Community Health (ACH) is stepping forward to help guide the path ahead. Last week, Advocates for Community Health (ACH) officially kicked off its 340B Learning Collaborative, bringing together health center 19 leaders from 15 states for a focused, solutions-driven effort to strengthen […]
In this episode of Community Health Centers Unfiltered, Advocates for Community Health goes beyond the headlines to explore how federal health policy is actually made — and what that process means for the stability and sustainability of community health centers (CHCs). Co-Host Margaret French of Venn Strategies is joined by Debbie Curtis and Rodney Whitlock […]
The federal healthcare landscape is shifting rapidly, but community health centers (CHCs) continue to demonstrate how community-driven primary care can meet the moment. That was the clear message from Advocates for Community Health’s 5th Annual Member Meeting, where health center leaders, federal officials, and policymakers gathered in Washington to chart the next chapter in health […]
